ConductScience.org, home

Comparison · NCT01617096-2d0296b9

Dapivirine Vaginal Ring vs Placebo Ring: Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dapivirine Vaginal Ring vs Placebo Ring: Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. Trial comparisons, record NCT01617096-2d0296b9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01617096-2d0296b9

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.05410.04310.0677wilson
Risk in group 20.07390.06090.0893wilson
Risk difference, group 1 minus group 2-0.0198-0.0387-0.00104newcombe hybrid score
Risk ratio, group 1 over group 20.7320.5440.984log
Odds ratio, group 1 over group 20.7170.5220.983log
Number needed to treat, for one fewer participant with the outcome on Dapivirine Vaginal Ring than on Placebo Ring50.525.8961from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Dapivirine Vaginal RingVaginal ring containing 25mg dapivirine~Dapivirine Vaginal Ring: Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months711,313OG000
Group 2Placebo RingVaginal ring containing no drug substance~Placebo Ring: Vaginal ring containing no drug substance971,313OG001

Outcome

Type
PRIMARY
Title
Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial.
Description
The primary endpoint is HIV-1 seroconversion as measured by rapid and specialised laboratory testing according to comprehensive HIV testing algorithm. Endpoint confirmation of HIV infection is by Western Blot.
Time frame
minimum of 12 months and a maximum of 14 months per participant
Population
The primary effectiveness Cohort included all eligible randomised participants excluding participants deemed to be HIV-1 RNA positive at the time of randomization, based on retrospective PCR testing of stored blood samples taken at enrollment.

Source ClinicalTrials.gov

Trial

Title
Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women
NCT number
NCT01617096
Phases
PHASE3
Conditions
HIV Infections
Interventions
Dapivirine Vaginal Ring, Placebo Ring
Lead sponsor
International Partnership for Microbicides, Inc.
Results first posted
2022-12-16

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01617096-2d0296b9